Optimal therapy recommendation for the use of solvent/detergent-treated human plasma

In response, CADTH initiated a pilot project and convened a Panel of Experts to evaluate the clinical and cost-effectiveness of S/D plasma versus standard plasma and to also consider the ethical implications of providing S/D plasma under certain criteria. [...] The Panel of Experts considered the results of an economic analysis which showed that the incremental cost-effectiveness ratio (ICER) (which takes into account the cost differential between FP and S/D plasma, as well as the potential additional clinical benefits of S/D plasma versus FP and patient preferences regarding such benefits) is very high Optimal Therapy Recommendation for the Use of Solve [...] In the case of plasma products, the Panel of Experts acknowledged that the overall transfusion risks are low, but, for patients targeted by the recommendation, risks are higher given the high volume of plasma transfusions they receive. [...] Although the quantity and quality of the clinical evidence is poor, the Panel of Experts acknowledged that the feasibility of conducting a large RCT is difficult because of the low prevalence of the conditions of interest. [...] Cost-Effectiveness The Panel of Experts considered an updated economic evaluation comparing the cost- effectiveness of S/D plasma and FP in reducing the risk of transmitting viruses.